A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
⚠ Elevated registrations this week are mostly phase-unspecified and may reflect a registry batch load rather than a real-world surge — interpret week-over-week with caution.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Responsible party does not work at UV anymore
This decision is based on a strategic company decision to discontinue development of this program as part of our portfolio prioritization.
opening up at a different site
Product expired, new lots are not available.
data analysis unequivocal - requires study methodology re-evaluation
recruitment difficulties
Novartis terminated the trial early because the collected data were sufficient to perform the analysis stated for the primary endpoint.
Administrative reasons.
The early termination of this study is justified by changes in the recommendations. Specifically, a paravertebral block-that is, a regional anesthesia technique-is now recommended. Consequently, subject recruitment has been halted.
Not moving forward with study.
Product expired, new lots not available
The study has not actually been conducted.
27 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| APOTEX | Unknown | 2026-07-10 |
| BELOTECA | ILOPROST | 2026-07-10 |
| LAURUS | RILPIVIRINE HYDROCHLORIDE | 2026-07-10 |
| PROVEPHARM SAS | INDOCYANINE GREEN INJECTION | 2026-07-10 |
| AJANTA PHARMA LTD | METFORMIN HYDROCHLORIDE, SITAGLIPTIN | 2026-07-09 |
| GLENMARK PHARMS LTD | NINTEDANIB ESYLATE | 2026-07-09 |
| AMNEAL EU LTD | SODIUM BICARBONATE | 2026-07-09 |
| SANOFI-AVENTIS U.S. LLC | ISATUXIMAB-IRFC | 2026-07-09 |
| LAURUS LABS LTD | TENOFOVIR ALAFENAMIDE FUMARATE | 2026-07-09 |
| SQUARE PHARMS PLC | MAGNESIUM SULFATE | 2026-07-09 |
| HUMANWELL PURACAP | NINTEDANIB ESYLATE | 2026-07-09 |
| ASPIRO | CYANOCOBALAMIN | 2026-07-08 |
| MACLEODS PHARMS LTD | DAPSONE | 2026-07-08 |
| BAXTER HLTHCARE CORP | EPHEDRINE SULFATE | 2026-07-08 |
| VERA THERAPEUTICS INC. | ATACIEPT-VYMJ | 2026-07-07 |
9.2% of the last year's EMA authorisations were conditional.
None authorised this period.
1 new · 0 resolved · 105 currently active.
| Newly reported shortage | Posted |
|---|---|
| Travoprost Ophthalmic Solution | 2026-07-07 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 64,713 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Cairo University | 4,739 |
| Assiut University | 4,705 |
| GlaxoSmithKline | 3,618 |
| National Cancer Institute (NCI) | 3,549 |
| Assistance Publique - Hôpitaux de Paris | 3,516 |
| AstraZeneca | 3,459 |
| Pfizer | 3,285 |
| Mayo Clinic | 3,217 |
| M.D. Anderson Cancer Center | 3,010 |
| Novartis Pharmaceuticals | 2,673 |
| National Taiwan University Hospital | 2,574 |
| Massachusetts General Hospital | 2,545 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,436 |
| Boehringer Ingelheim | 2,282 |
| University of California, San Francisco | 2,141 |
| Stanford University | 2,135 |
| Merck Sharp & Dohme LLC | 2,133 |
| Hoffmann-La Roche | 2,078 |
| Riphah International University | 2,074 |
| Eli Lilly and Company | 2,070 |
| Duke University | 2,042 |
| Memorial Sloan Kettering Cancer Center | 1,942 |
| Seoul National University Hospital | 1,881 |
| Ain Shams University | 1,848 |
| Hospices Civils de Lyon | 1,830 |
| Condition | Trials |
|---|---|
| breast cancer | 11,747 |
| obesity disorder | 9,492 |
| type 2 diabetes mellitus | 9,095 |
| chronic pain syndrome | 8,758 |
| HIV infectious disease | 8,177 |
| cancer | 8,154 |
| COVID-19 | 7,632 |
| non-small cell lung carcinoma | 6,290 |
| diabetes mellitus | 6,105 |
| hypertensive disorder | 6,104 |
| cerebrovascular disorder | 5,968 |
| colorectal cancer | 5,961 |
| coronary artery disorder | 5,915 |
| prostate cancer | 5,816 |
| depressive disorder | 5,796 |
| cardiovascular disorder | 5,577 |
| heart failure | 4,865 |
| anxiety disorder | 4,823 |
| injury | 4,428 |
| Parkinson disease | 4,409 |
| cognitive disorder | 4,136 |
| asthma | 4,112 |
| lung cancer | 4,050 |
| benign essential hypertension | 3,864 |
| neuralgia | 3,815 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,115 |
| paclitaxel | 5,389 |
| isoniazid | 5,288 |
| cyclophosphamide | 5,088 |
| prednisolone | 4,888 |
| ropivacaine | 4,817 |
| dexamethasone | 4,762 |
| bevacizumab | 4,556 |
| cisplatin | 4,433 |
| lidocaine | 3,575 |
| aspirin | 3,333 |
| gemcitabine | 3,160 |
| bupivacaine | 3,086 |
| desoxycorticosterone acetate | 2,979 |
| pembrolizumab | 2,957 |
| sitagliptin and metformin hydrochloride | 2,948 |
| metformin | 2,942 |
| rituximab | 2,914 |
| meprednisone | 2,850 |
| dapagliflozin metformin hydrochloride | 2,788 |
| sitagliptin metformin hydrochloride | 2,758 |
| docetaxel | 2,751 |
| linagliptin and metformin hydrochloride | 2,745 |
| fluorouracil | 2,688 |
| alogliptin and metformin hydrochloride | 2,687 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,090 | 860 | 890 |
| AstraZeneca | 1,016 | 550 | 799 |
| Pfizer | 1,171 | 709 | 652 |
| Novartis Pharmaceuticals | 508 | 834 | 734 |
| Boehringer Ingelheim | 1,065 | 322 | 399 |
| Merck Sharp & Dohme LLC | 696 | 549 | 737 |
| Hoffmann-La Roche | 491 | 480 | 567 |
| Eli Lilly and Company | 825 | 535 | 548 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Remdesivir | 2026-07-13 |
| Norgestrel | 2026-07-13 |
| Loteprednol Etabonate; Tobramycin | 2026-07-14 |
| Iohexol | 2026-07-26 |
| Alogliptin Benzoate | 2026-07-27 |
| Alogliptin Benzoate; Metformin Hydrochloride | 2026-07-27 |
| Octreotide Acetate | 2026-08-02 |
| Pexidartinib Hydrochloride | 2026-08-02 |
| Fedratinib Hydrochloride | 2026-08-16 |
| Valbenazine Tosylate | 2026-08-18 |
| Gallium Ga-68 Edotreotide | 2026-08-21 |
| Cobicistat | 2026-08-22 |
| Difelikefalin Acetate | 2026-08-23 |
| Sofosbuvir | 2026-08-28 |
| Ledipasvir; Sofosbuvir | 2026-08-28 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.